Clinical application of huang'e capsule after surgery for prostatic hyperplasia
Abstract
: The purpose of this study was to observe the clinical effect and safety of huangʼe capsule on the improvement of symptoms after surgery for benign prostatic hyperplasia. We used random sampling to divide 14 patients with benign prostatic hyperplasia into the experimental group and the control group, with 7 cases in each group. The experimental group was given 4 capsules each time, 3 times a day for 42 days after surgery, while the control group did not receive the treatment of huangʼe capsules. The International Prostatic Hyperplasia Symptom Score (I-PSS), Maximal Uroflow Rate Change (Qmax), Quality of Life Score (QOL) and liver and kidney function indexes were observed in the two groups before and after surgery. The results shows that the postoperative I-PSS, Qmax and QOL of the two groups were significantly improved (P<0.05), while the efficacy of the experimental group was better (P<0.05). The liver and kidney function indexes of the experimental group before and after treatment were within the normal range. It was concluded that Huangʼe capsule could effectively improve the postoperative clinical efficacy of patients with prostatic hyperplasia and had good safety.
Read the paper
Related studies
- Treatment of non-metastatic castration-resistant prostate cancer: facing age-related comorbidities and drug–drug interactions
- The Efficacy of Flogofilm® in the Treatment of Chronic Bacterial Prostatitis as an Adjuvant to Antibiotic Therapy: A Randomized Prospective Trial
- Inhibition of growth and contraction in human prostate stromal cells by silencing of NUAK1 and -2, and by the presumed NUAK inhibitors HTH01-015 and WZ4003
- Effectiveness and Safety of a New Nutrient Fixed Combination Containing Pollen Extract Plus Teupolioside, in the Management of LUTS in Patients with Benign Prostatic Hypertrophy: A Pilot Study
- Extract from Cucurbita pepo improves BPH symptoms without affecting sexual function: a 24-month noninterventional study
- Aquablation vs. holmium laser enucleation of the prostate for benign prostatic hyperplasia: a 150-patients prospective comparative multicenter study
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.